SCHEMBL1491101

SCHEMBL1491101

Nc1ccnn1Cc1ccccc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
GAA P10253 2/20 0.58
KDM4E B2RXH2 1/20 0.56
POLB P06746 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
RAB9A P51151 1/20 0.51
BLM P54132 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
GPR35 Q9HC97 1/20 0.51
ALDH1A1 P00352 3/20 0.50
PKM P14618 1/20 0.50
TNF P01375 1/20 0.46
NOD2 Q9HC29 1/20 0.46
NOD1 Q9Y239 1/20 0.46
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
CYP2A13 Q16696 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1491114 0.81 KDM4E (0.50) MEN1KMT2AGAAKDM4ESMN1; SMN2
SCHEMBL1491068 0.81 ALDH1A1 (0.51) MEN1KMT2AKDM4EPOLBRAB9A
SCHEMBL11654507 0.80 KDM4E (0.58) GAAKDM4EPOLBSMN1; SMN2RAB9A
SCHEMBL568868 0.79 KDM4E (0.72) MEN1KMT2AGAAKDM4EPOLB
SCHEMBL11651616 0.79 KDM4E (0.53) KDM4EPOLBSMN1; SMN2RAB9AALDH1A1
SCHEMBL1491106 0.77 KDM4E (0.46) KMT2AKDM4EPOLBNPSR1ALDH1A1
SCHEMBL1491059 0.77 NPBWR1 (0.48) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL6760429 0.77 KDM4E (0.81) MEN1KMT2AGAAKDM4EPOLB
SCHEMBL4805694 0.76 ALDH1A1 (0.56) MEN1KMT2AGAAPOLBSMN1; SMN2
SCHEMBL10639487 0.76 MEN1 (0.59) MEN1KMT2AGAAPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110114351-A The heterocycle inhibitor of MCT4 维托尔股份有限公司 2019-08-09 CN disclosed
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-04-14 US disclosed
EP-2288603-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2011-03-02 EP disclosed
WO-2009150614-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-12-17 WO disclosed
US-4097475-A FOR POLYESTERS AND BLENDS WITH CELLULOSE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R MEN1 683/4885KMT2A 1510/4885GAA 2218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.